BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33382126)

  • 1. Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.
    Wilson J; Yarnall AJ; Craig CE; Galna B; Lord S; Morris R; Lawson RA; Alcock L; Duncan GW; Khoo TK; O'Brien JT; Burn DJ; Taylor JP; Ray NJ; Rochester L
    Mov Disord; 2021 Mar; 36(3):611-621. PubMed ID: 33382126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.
    Ray NJ; Bradburn S; Murgatroyd C; Toseeb U; Mir P; Kountouriotis GK; Teipel SJ; Grothe MJ
    Brain; 2018 Jan; 141(1):165-176. PubMed ID: 29228203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gait variability is linked to the atrophy of the Nucleus Basalis of Meynert and is resistant to STN DBS in Parkinson's disease.
    Wilkins KB; Parker JE; Bronte-Stewart HM
    Neurobiol Dis; 2020 Dec; 146():105134. PubMed ID: 33045357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson's disease.
    Schumacher J; Kanel P; Dyrba M; Storch A; Bohnen NI; Teipel S; Grothe MJ
    Brain; 2023 Dec; 146(12):4964-4973. PubMed ID: 37403733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal Forebrain Atrophy, Cortical Thinning, and Amyloid-β Status in Parkinson's disease-Related Cognitive Decline.
    Labrador-Espinosa MA; Silva-Rodríguez J; Reina-Castillo MI; Mir P; Grothe MJ
    Mov Disord; 2023 Oct; 38(10):1871-1880. PubMed ID: 37492892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease.
    Pereira JB; Hall S; Jalakas M; Grothe MJ; Strandberg O; Stomrud E; Westman E; van Westen D; Hansson O
    Neurobiol Dis; 2020 Jun; 139():104831. PubMed ID: 32145376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Cerebral Metabolic Changes in Parkinson's Disease With Basal Forebrain Atrophy.
    Gang M; Baba T; Hosokai Y; Nishio Y; Kikuchi A; Hirayama K; Hasegawa T; Aoki M; Takeda A; Mori E; Suzuki K
    Mov Disord; 2020 May; 35(5):825-832. PubMed ID: 31971293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free-water imaging of the cholinergic basal forebrain and pedunculopontine nucleus in Parkinson's disease.
    Ray NJ; Lawson RA; Martin SL; Sigurdsson HP; Wilson J; Galna B; Lord S; Alcock L; Duncan GW; Khoo TK; O'Brien JT; Burn DJ; Taylor JP; Rea RC; Bergamino M; Rochester L; Yarnall AJ
    Brain; 2023 Mar; 146(3):1053-1064. PubMed ID: 35485491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent and additive contribution of white matter hyperintensities and Alzheimer's disease pathology to basal forebrain cholinergic system degeneration.
    Kindler C; Upadhyay N; Bendella Z; Dorn F; Keil VC; Petzold GC
    Neuroimage Clin; 2023; 39():103477. PubMed ID: 37478584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased basal forebrain volumes could prevent cognitive decline in LRRK2 Parkinson's disease.
    Batzu L; Urso D; Grothe MJ; Veréb D; Chaudhuri KR; Pereira JB
    Neurobiol Dis; 2023 Jul; 183():106182. PubMed ID: 37286171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease.
    Wilson H; de Natale ER; Politis M
    Handb Clin Neurol; 2021; 179():189-205. PubMed ID: 34225962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration.
    Fernández-Cabello S; Kronbichler M; Van Dijk KRA; Goodman JA; Spreng RN; Schmitz TW;
    Brain; 2020 Mar; 143(3):993-1009. PubMed ID: 32203580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleus basalis of Meynert predicts cognitive changes in isolated REM sleep behavior disorder.
    Yang A; Li G
    Sleep Med; 2023 Sep; 109():11-17. PubMed ID: 37393717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrophy of the Cholinergic Basal Forebrain can Detect Presynaptic Cholinergic Loss in Parkinson's Disease.
    Ray NJ; Kanel P; Bohnen NI
    Ann Neurol; 2023 May; 93(5):991-998. PubMed ID: 36597786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinergic basal forebrain and hippocampal structure influence visuospatial memory in Parkinson's disease.
    Berlot R; Pirtošek Z; Brezovar S; Koritnik B; Teipel SJ; Grothe MJ; Ray NJ
    Brain Imaging Behav; 2022 Feb; 16(1):118-129. PubMed ID: 34176042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleus basalis of Meynert neuronal activity in Parkinson's disease.
    Lee DJ; Milosevic L; Gramer R; Sasikumar S; Al-Ozzi TM; De Vloo P; Dallapiazza RF; Elias GJB; Cohn M; Kalia SK; Hutchison WD; Fasano A; Lozano AM
    J Neurosurg; 2019 Feb; 132(2):574-582. PubMed ID: 30797189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrity of the nucleus basalis of meynert and self-reported cognitive dysfunction during wearing-off periods in parkinson's disease.
    Lench DH; Turner TH; Wetmore E; Rodriguez-Porcel FJ; Revuelta GJ
    Brain Imaging Behav; 2024 Feb; 18(1):256-261. PubMed ID: 37889445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinergic basal forebrain atrophy in Parkinson's disease with freezing of gait.
    Gan C; Cao X; Wang L; Sun H; Ji M; Zhang H; Yuan Y; Zhang K
    Ann Clin Transl Neurol; 2023 May; 10(5):814-824. PubMed ID: 37000969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinergic basal forebrain system degeneration underlies postural instability/gait difficulty and attention impairment in Parkinson's disease.
    Wu C; Wu H; Zhou C; Guan X; Guo T; Cao Z; Wu J; Liu X; Chen J; Wen J; Qin J; Tan S; Duanmu X; Yuan W; Zheng Q; Zhang B; Huang P; Xu X; Zhang M
    Eur J Neurol; 2024 Feb; 31(2):e16108. PubMed ID: 37877681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study.
    Grothe MJ; Labrador-Espinosa MA; Jesús S; Macías-García D; Adarmes-Gómez A; Carrillo F; Camacho EI; Franco-Rosado P; Lora FR; Martín-Rodríguez JF; Barberá MA; Pastor P; Arroyo SE; Vila BS; Foraster AC; Martínez JR; Padilla FC; Morlans MP; Aramburu IG; Ceberio JI; Vara JH; de Fábregues-Boixar O; de Deus Fonticoba T; Pascual-Sedano B; ; Kulisevsky J; Martínez-Martín P; Santos-García D; Mir P
    Parkinsonism Relat Disord; 2021 Jul; 88():68-75. PubMed ID: 34144230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.